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Abstract
Purpose
To evaluate risk factors associated with alterations in venous structures adjacent to an abla-
tion zone after percutaneous irreversible electroporation (IRE) of hepatic malignancies at
subacute follow-up (1 to 3 days after IRE) and to describe evolution of these alterations at
mid-term follow-up.
Materials and Methods
43 patients (men/women, 32/11; mean age, 60.3 years) were identified in whom venous
structures were located within a perimeter of 1.0 cm of the ablation zone at subacute follow-
up after IRE of 84 hepatic lesions (primary/secondary hepatic tumors, 31/53). These ves-
sels were retrospectively evaluated by means of pre-interventional and post-interventional
contrast-enhanced magnetic resonance imaging or computed tomography or both. Any
vascular changes in flow, patency, and diameter were documented. Correlations between
vascular change (yes/no) and characteristics of patients, lesions, and ablation procedures
were assessed by generalized linear models.
Results
191 venous structures were located within a perimeter of 1.0 cm of the ablation zone: 55
(29%) were encased by the ablation zone, 78 (41%) abutted the ablation zone, and 58
(30%) were located between 0.1 and 1.0 cm from the border of the ablation zone. At sub-
acute follow-up, vascular changes were found in 19 of the 191 vessels (9.9%), with partial
portal vein thrombosis in 2, complete portal vein thrombosis in 3, and lumen narrowing in 14
of 19. At follow-up of patients with subacute vessel alterations (mean, 5.7 months; range, 0
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to 14 months) thrombosis had resolved in 2 of 5 cases; vessel narrowing had completely
resolved in 8 of 14 cases, and partly resolved in 1 of 14 cases. The encasement of a vessel
by ablation zone (OR = 6.36, p<0.001), ablation zone being adjacent to a portal vein (OR =
8.94, p<0.001), and the usage of more than 3 IRE probes (OR = 3.60, p = 0.035) were inde-
pendently associated with post-IRE vessel alterations.
Conclusion
Venous structures located in close proximity to an IRE ablation zone remain largely unaf-
fected by this procedure, and thrombosis is rare.
Introduction
Thermal ablation of tumors adjacent to major liver vessels remains challenging: on the one
hand, because the “heat sink” effect leads to the loss of thermal energy by convection and thus
increases the risk of incomplete ablation [1–3], and, on the other hand, because of the risk of
vessel damage, especially of the endothelium [4].
Irreversible electroporation (IRE) as a non-thermal ablative option seems to overcome
those above mentioned limitations of thermal ablation procedures: histopathological animal
studies have shown that IRE induces cell death up to a vessel wall without any perivascular
sparing [5–7] whilst preserving the normal architecture of blood vessels [5, 6, 8, 9]. However,
mild histopathological changes in adjacent vessel walls as vasculitis and mild endothelial dam-
age have been detected in animal studies [5, 8, 10]. Additionally, alterations of vessels adjacent
to an IRE ablation zone were detected by means of computed tomography (CT) imaging after
IRE on porcine livers [6]. Similar findings have been reported after IRE ablation of 129 tumors
in different organs in humans [11].
The objective of this retrospective study was to evaluate risk factors associated with alter-
ations in venous structures adjacent to an ablation zone after IRE of hepatic malignancies in
humans at subacute follow-up. Additionally, the evolution of these changes was evaluated by
means of further follow-up imaging.
Material and Methods
Study design, participant selection, and patient characteristics
A single-center retrospective observational study was conducted to describe alterations in
venous structures after percutaneous IRE of malignant liver tumors evaluated by means of con-
trast-enhanced magnetic resonance imaging (MRI) or CT. The study was approved by the
local ethics committee (Ethics Committee of the University of Regensburg). Each patient
signed an informed consent form for the ablation procedure, the acquisition of contrast-
enhanced CT or MRI images, or both, and the anonymous use of data for scientific purposes.
Patients were included in this study if they fulfilled the following criteria: (1) Patients were
suffering from primary or secondary liver malignancy. (2) Liver tumors were treated by percu-
taneous IRE. (3) Patients had undergone a contrast-enhanced MRI or CT scan of the whole
liver during the portal venous phase before and after each intervention. (4) Post-ablative imag-
ing had to be conducted at the subacute follow-up (i.e. 1 to 3 days after the ablation). (5)
Venous structures (portal veins [PVs], hepatic veins [HVs], inferior vena cava [IVC], and
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transjugular intrahepatic portosystemic shunt [TIPS]) were located within a perimeter of 1 cm
of the ablation zone at subacute follow-up.
A prior treatment of liver malignancies by systemic chemotherapy, radiotherapy, surgery,
or IRE ablation was no exclusion criterion.
43 patients (32 men and 11 women) aged 60.3 years ± 11.9 (range, 22 to 80 years) who had
undergone IRE ablation of 84 hepatic lesions in 63 ablation procedures fulfilled the above men-
tioned inclusion criteria and were included in this study (Table 1). 31 of the 84 lesions (number
of patients, 20) were primary liver tumors, and 53 (number of patients, 23) were secondary
liver tumors (Table 2). The mean tumor diameter was 2.4 cm ± 1.1 (range, 0.5 to 6.3 cm). 48
sessions involved the ablation of 1 tumor and 15 sessions the ablation of 2 to 4 tumors.
Two radiologists with 3 years and 9 years of experience in abdominal imaging, respectively,
examined each subacute follow-up image for possible vascular changes in diameter, patency,
Table 1. Baseline patient characteristics.
Characteristic
Age (y), mean (SD), range 60.3 (11.9), 22–80
Sex, n (%)
Male 32 (74.4)
Female 11 (25.6)
Patients with cirrhosis, n (%) 16 (37.2)
Child-Pugh class A 5 (11.6)
Child-Pugh class B 10 (23.3)
Child-Pugh class C 1 (2.3)
History of atherothrombosis#, n (%) 7 (16.3)
History of DVT, n (%) 2 (4.7)
History of pulmonary embolism, n (%) 0
Arterial hypertension, n (%) 7 (16.3)
Diabetes mellitus, n (%) 14 (32.6)
Anticoagulative medication, n (%) 13 (30.2)
#history of ischemic stroke and/or myocardial infarction and/or aortic valve calciﬁcation and/or peripheral
artery occlusive disease
doi:10.1371/journal.pone.0135773.t001
Table 2. Tumor types in 43 patients treated with irreversible electroporation of malignant liver
tumors.
Diagnosis No. Patients No. treated lesions
Primary liver tumors
Hepatocellular carcinoma 16 25
Cholangiocellular carcinoma 4 6
Metastases of
Colorectal tumor 16 39
Mammarian carcinoma 2 6
Neuroendocrinic tumor 1 2
Other# 4 6
Total 43 84
#testicular tumor, gastrinoma, esophageal cancer, carcinoma of unknown origin
doi:10.1371/journal.pone.0135773.t002
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and flow in a consensus reading; the evolution of such vessel alterations was evaluated by
means of further follow-up imaging (MRI or CT scans, or both).
Ablation procedure
All ablation procedures were performed percutaneously under CT fluoroscopy guidance using
the NanoKnife System (AngioDynamics, Latham, New York). The IRE parameters were as fol-
lows: electric field, 1500 V/cm needle distance; pulse length, 90 μs; pulses per cycle, 70. Post-
interventionally all patients received 20 mg enoxaparin subcutaneously once a day until full
mobilization.
Statistical analysis
Data are presented as frequency counts and percentages. To take account for multiple vessels
per patient, marginal generalized linear models (GLM) were used to identify variables for pre-
diction of vascular changes at subacute follow-up. The mean response was modeled as a logistic
regression model. The binary response for individual patients was assumed to be equally corre-
lated, implying an exchangeable correlation structure. Maximum-likelihood odds-ratio estima-
tors (OR) and 95% confidence intervals are presented as effect estimates. Univariate models as
well as one multivariable model, including all variables with p<0.1 in the univariate model
were calculated. Associations were considered significant for p<0.05. All statistical analyses
were performed with SAS 9.4. Variables analyzed were age (<65y vs65y), sex, the presence
of hypertension, anticoagulative therapy, diabetes mellitus, liver cirrhosis, atherosclerosis, sta-
tus post deep vein thrombosis, nature vessel being adjacent to ablation zone (PV vs HV/IVC/
TIPS), and localization of vessel with regard to ablation zone (encased vs abutting/distant).
Results
In these 43 patients 191 venous structures were located within a perimeter of 1.0 cm of the
ablation zone; details regarding vessel location and vessel type are listed in Table 3. At subacute
follow-up in 172 of 191 vessels (90.1%) no vascular alteration was noted (Fig 1), in 19 vessels
Table 3. The type and number of vessels adjacent to the ablation zone and number of vessels with vascular alterations with regard to their
localization.
Vessel Total number of vessels/number of vessels with
vascular alterations
Number of vessels in location regarding ablation zone/number
of vessels with vascular alterations
Encased/
altered
Abutting/
altered
Within a perimeter of 0.1–1.0
cm/altered
Main PV 7/0 1/0 0/0 6/0
Right PV or segmental PV
branch
39/5 13/5 16/0 10/0
Left PV or segmental PV
branch
31/11 10/7 9/3 12/1
Middle HV 36/1 13/1 16/0 7/0
Right HV 38/1 13/0 14/0 11/1
Left HV 22/0 5/0 11/0 6/0
IVC 17/1 0/0 11/0 6/1
TIPS stent 1/0 0/0 1/0 0/0
Total 191/19 55/13 78/3 58/3
PV, portal vein; HV, hepatic vein; IVC, inferior vena cava; TIPS, transjugular intrahepatic portosystemic shunt
doi:10.1371/journal.pone.0135773.t003
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(9.9%) in 17 patients post-IRE alterations were detected (Tables 3 and 4; Fig 2): in particular
changes of PV, HV, IVC, and TIPS were noted in 16 of 77 (20.8%), 2 of 96 (2.1%), 1 of 17
(5.9%), and 0 of 1 (0%) of cases, respectively (Table 3). 14 of the 19 alterations (14 of 191
[7.3%]) consisted of vessel narrowing (Fig 3). 2 and 3 of the 19 post-ablative alterations (2 of
191 [1.0%] and 3 of 191 [1.6%)]) consisted of partial and complete PV thrombosis, respectively
(Fig 4). The mean period for a further post-interventional follow-up scan after subacute imag-
ing, which was available in 16 of 17 patients, was 5.7 months ± 4.1 (range, 0 to 14 months).
In the univariate GLMs, number of IRE needles (3 vs.>3), the presence of diabetes melli-
tus (no vs yes), the type of affected vessel (PV vs HV/IVC/TIPS) and vessel location with regard
to ablation zone (encased vs abutting/distant) were significant risk factors for the occurrence of
vessel alterations. In the multivariable model number of IRE needles, type of affected vessel
and vessel location with regard to ablation zone remained significant (Table 5).
Discussion
As a non-thermal ablative method, IRE has shown promising results in ablating perivascular
tissue. Preliminary animal studies on the IRE ablation of perivascular porcine liver tissue
have shown that this method is not affected by the common heat sink phenomenon [7, 12].
Complete tissue ablation up to the vessel wall could be achieved without any perivascular
sparing, and vessels within the ablation zone remained patent at follow-up [6, 10, 12]. Similar
results have been reported by Lee and colleagues after IRE ablation of VX2 tumors in rodent
livers [13].
A retrospective review of safety and efficacy of IRE in the clinical setting was published by
Scheffer and colleagues [14]: Their results included 129 patients in whom hepatic malignancies
were ablated by IRE using an open, laparoscopic, or percutaneous approach. In this review por-
tal vein thromboses/occlusions after hepatic IRE had occurred in 1 case in one study: Kingham
et al. [15] evaluated safety of IRE ablation of 65 liver tumors being juxtaposed to main hepatic
vessels: 25 and 16 tumors were located within a perimeter of 1 cm of a major HV and a major
portal pedicle, respectively; only 1 patient had developed post-ablative thrombosis within a
portal pedicle. In a recent study not included in the above mentioned review, Narayanan and
colleagues [11] have treated 101 patients with 129 lesions, mostly hepatic tumors (100 of 129),
Fig 1. A 71-year old women with centrally located metastasis of colorectal cancer in Couinaud segment VIII of the liver. (A) On pre-interventional
contrast-enhanced portal venous image the right hepatic vein (thin arrows) is directly adjacent to the hepatic metastasis (only partly shown on this layer,
arrow heads). (B) The post-interventional image 3 days after IRE shows that the right hepatic vein (thin arrows) is encased by the ablation zone (thick
arrows), but no vessel narrowing or thrombotic changes are detectable.
doi:10.1371/journal.pone.0135773.g001
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Table 4. Patients with vascular changes at subacute follow-up imaging (i.e. 1–3 days after ablation), type of altered vessel, location of vessel with
regard to IRE ablation zone and IRE needles, kind of vascular alteration, vessel diameter at subacute follow-up imaging and its evolution at follow-
up imaging.
Patient
No
Vessel Vessel
location
with regard
to ablation
zone§
Minimum
distance of
vessel to IRE
needle
Kind of
vascular
alteration at
subacute
follow-up
Vessel diameter at
subacute follow-up
in relation to pre-
interventional
diameter
Further
follow-
up
Vessel diameter at
further follow-up in
relation to pre-
interventional
diameter
Evolution of
subacute vascular
alteration at further
follow-up
1# rPVsb e 0.3 cm Lumen
narrowing
57% 3 mo 100% Resolved
1# mHV e 0.5 cm Lumen
narrowing
66% 3 mo 100% Resolved
2* rPVsb e 0.6 cm Lumen
narrowing
40% 6 mo 70% Partly resolved
2* lPV d (0.8 cm) 1.5 cm Partial
thrombosis
— 7 mo — Resolved
3 rPV e 0.4 cm Lumen
narrowing
67% 4 mo 100% Resolved
4 rPV e 0.2 cm Lumen
narrowing
14% 2 mo 100% Resolved
5 rPV e 0.7 cm Lumen
narrowing
66% 11 mo 60% Progressive lumen
narrowing due to
local tumor
progression
6 lPVsb a 0.3 cm Lumen
narrowing
50% 3 mo 100% Resolved
7 lPVsb e 0.8 cm Lumen
narrowing
33% 6 mo 100% Resolved
8 lPVsb e 0.3 cm Lumen
narrowing
66% 9 mo 66% Persistent lumen
narrowing, no local
tumor progression
9 lPVsb e 0.7 cm Lumen
narrowing
66% 0 — No follow-up due to
resection of lPV and
left liver lobe as
planned before IRE
10 lPV a 0.5 cm Complete
thrombosis
— 14 mo — Thrombosis
persisted; volume
reduction of left liver
lobe; no infarction
11 lPVsb e 0.6 cm Complete
thrombosis
— 12 mo — Infarction of
Couinaud liver
segments II and III;
thrombosis persisted
12 lPVsb e 0.3 cm Lumen
narrowing
57% 8 mo 100% Resolved
13 lPVsb e 0.4 cm Complete
thrombosis
— 7 d — Resolved, no
infarction
14 lPVsb e 0.5 cm Lumen
narrowing
63% 4 mo 100% Resolved
15 lPVsb a 0.9 cm Partial
thrombosis
— 3 mo — Persistent
thrombosis; volume
reduction of left liver
lobe; no infarction
(Continued)
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Table 4. (Continued)
Patient
No
Vessel Vessel
location
with regard
to ablation
zone§
Minimum
distance of
vessel to IRE
needle
Kind of
vascular
alteration at
subacute
follow-up
Vessel diameter at
subacute follow-up
in relation to pre-
interventional
diameter
Further
follow-
up
Vessel diameter at
further follow-up in
relation to pre-
interventional
diameter
Evolution of
subacute vascular
alteration at further
follow-up
16 rHV d (1.0 cm) 1.4 cm Lumen
narrowing
56% 2 mo 0 Complete
thrombosis
secondary to new
hepatic mass at the
conﬂuence of the
rHV and the IVC
17 IVC d (0.8 cm) 1.0 cm Lumen
narrowing
53% 9 mo 53% Persistent lumen
narrowing, no local
tumor progression
IRE, irreversible electroporation; lPV, left portal vein; lPVsb, left portal vein segmental branch; rPV, right portal vein; rPVsb, right portal vein segmental
branch; mHV, middle hepatic vein, rHV, right hepatic vein; IVC, inferior vena cava; e, encased; a, abutting; d, within a perimeter of 0.1–1.0 cm; mo,
months; d, days;
#same procedure,
*different procedures;
§in the case of “d” (i.e. within a perimeter of 0.1–1.0 cm) the exact distance from border of the ablation zone is mentioned in parentheses.
doi:10.1371/journal.pone.0135773.t004
Fig 2. Percentage and absolute numbers of vessels with/without alterations with regard to their
location to ablation zone.
doi:10.1371/journal.pone.0135773.g002
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with IRE ablation. 158 vessels located within a perimeter of 1 cm of the treatment zone were
evaluated in the follow-up; abnormal alterations occurred in 7 of 158 vessels (4.4%) including
thrombosis in the portal venous system (n = 4) and mild narrowing of the PV (n = 2) and the
HV (n = 1).
The current study focussed on vessel alterations after IRE ablation of hepatic tumors. Post-
ablative IRE-related vessel alterations had occurred in 19 of 191 cases (9.9%), mainly consisting
of lumen narrowing (14 of 19), which were high-grade stenosis in select cases. After IRE in por-
cine livers Lee et al. [6] reported lumen narrowing of HVs at subacute follow-up in 39% (9 of
23) of HVs which showed contiguity to IRE lesions. A further follow-up was available in 3 of
the 9 cases: 2 of the 3 narrowed HVs had extended to their normal caliber at the 4-week follow-
up, but 1 of the 3 narrowed HVs had remained unchanged at the 2-day follow-up. As an under-
lying reason, Lee and colleagues presumed post-ablative hyperemic, inflammatory, and
Fig 3. A 63-year old women (patient #4) with centrally locatedmetastasis (not shown) of colorectal cancer. (A) Pre-interventional contrast-enhanced
T1wmagnetic resonance imaging (MRI) shows a freely perfused right branch of the portal vein (thin arrow). (B) A T1wMRI image obtained on the 3rd post-
interventional day shows a caliber reduction of the right portal vein (thin arrow) encased by the ablation zone (thick arrows). (C) 6 weeks after the intervention,
the lumen reduction of the right portal vein has resolved (thin arrow).
doi:10.1371/journal.pone.0135773.g003
Fig 4. A 75-year old man (patient #15) with hepatocellular carcinoma. (A) Pre-interventional contrast-enhanced T1wmagnetic resonance imaging shows
a freely perfused portal vein (thin arrow); HCC lesion is partly visible (thick arrows). (B) 1 day after the ablation, the T1w image shows the ablation zone (thick
arrows) and newly occurred partial thrombosis of the left portal vein (thin arrow). (C) At the 4-month follow-up, partial thrombosis of the left portal vein has
persisted (thin arrow), and the ablation zone has decreased (thick arrows).
doi:10.1371/journal.pone.0135773.g004
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edematous changes in ablated tissue and the surrounding intact liver parenchyma as reported
in preliminary studies [7, 8, 16, 17]. Since moderate caliber reduction of venous structures adja-
cent to the ablation zone is to be expected because of the above-mentioned changes in ablated
tissue and surrounding liver parenchyma at subacute follow-up, the authors of the current
study consider such alterations a common occurrence. Post-IRE vessel alterations occurred sig-
nificantly more frequent if more than 3 IRE electrodes were used (p = 0.0266) and if a vessel
was encased by the ablation zone (p< 0.0001) compared to vessels which were distant from or
abutting the ablation zone. In the current study 2 of 14 cases of lumen narrowing at subacute
follow-up have persisted at 9-month follow-up after ablation, and in a third case lumen nar-
rowing has only partly resolved 6 months after the ablation; in neither of the 3 cases there was
local tumor progression. This kind of persistent vessel narrowing could have been caused by
scarring after IRE as described in preliminary studies [7, 17].
All thromboses in this study (n = 5) occurred in the portal venous system: 1 of the 5 cases
had resolved within 1 week and another case within 6 months. 3 of the 5 cases of thromboses
had persisted and resulted in reduced liver volume in each case and in additional partial liver
infarction in 1 case. The finding of thromboses within the portal venous system in the current
study is in line with the results found by Narayanan et al. [11] who detected post-IRE vascular
thrombosis only in PVs (n = 4). The authors proposed a greater vulnerability of PVs to IRE-
induced vessel damage due to special flow dynamics within these vessels. The statistical analy-
sis of the current study emphasizes this assumption of Narayanan et al. with PVs being signifi-
cantly more frequently altered (p = 0.0002) compared to HVs and IVC. These patients with
post-IRE portal vein (branch) thrombosis had a mean age of 67.8 y (range, 54–80) with two of
them having liver cirrhosis, none of them having a known atherosclerotic disease and two of
them were under anticoagulation. Because of the risk of IRE-related thrombosis within the por-
tal venous system, special caution should be exercised in patients with significantly reduced
liver volume, for instance after liver resection, and in patients with impaired liver function to
avoid liver infarction.
This study has several limitations: One is the difference in imaging modalities during fol-
low-up as well as variations in follow-up periods. Moreover data were analyzed retrospectively
Table 5. Results of generalized linear models predicting vessel alterations.
Univariate models Multivariable model*
Odds Ratio (95%-CI) p-value Odds Ratio (95%-CI) p-value
Age (ref: <65y vs 65y) 1.72 (0.84, 3.52) 0.140
Number of IRE needles (ref:  3 vs >3) 4.96 (1.13, 21.82) 0.034 3.60 (1.09, 11.88) 0.035
Sex (ref: male vs female) 1.61 (0.84, 3.08) 0.151
Hypertension 0.44 (0.07, 2.62) 0.367
Anticoagulation 1.41 (0.64, 3.13) 0.395
Diabetes mellitus 2.02 (1.01, 4.05) 0.048 1.88 (0.86, 4.08) 0.112
Liver cirrhosis 1.39 (0.66, 2.93) 0.387
Atherosclerosis 1.98 (0.67, 5.86) 0.215
S/p DVT 1.71 (0.70, 4.17) 0.240
Vessel type (ref: no PV vs PV) 10.12 (2.85, 35.97) <0.001 8.94 (2.65, 30.16) <0.001
Vessel location (ref: not encased vs encased) 5.73 (3.02, 10.91) <0.001 6.36 (2.58, 15.65) <0.001
IRE, irreversible electroporation; DVT, deep vein thrombosis; S/p, status post; PV, portal vein; no PV, HV or IVC or TIPS; not encased, abutting or distant;
*includes all variables with p<0.1 in the univariate model.
doi:10.1371/journal.pone.0135773.t005
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and the study group consisted of a heterogeneous patient population with primary and second-
ary hepatic tumors. Furthermore most patients had undergone a previous tumor treatment
with chemotherapy, radiotherapy, or both, which could have damaged blood vessels and con-
secutively made them more susceptible for further IRE-induced damage.
Conclusion
The current study showed that venous structures located in close proximity to an IRE ablation
zone remain largely unaffected by this procedure and that thrombotic vessel changes are rare.
Supporting Information
S1 Table. Characteristics of patients, ablated tumors and adjacent vessels.
(XLSX)
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